INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants
Viviane M. Andrade, Aaron Christensen-Quick, Joseph Agnes, Jared Tur, Charles C. Reed, Richa Kalia, Idania Marrero, Dustin Elwood, Katherine Schultheis, Mansi Purwar, Emma L. Reuschel, Trevor McMullan, Patrick Pezzoli, Kim Kraynyak, Albert J. Sylvester, Mammen P. Mammen, Pablo Tebas, J Joseph Kim, David B. Weiner, Trevor R.F. Smith, Stephanie Ramos, Laurent Humeau, Jean Boyer, Kate E. Broderick
Abstract
Global surveillance has identified emerging SARS-CoV-2 variants of concern (VOC) associated with broadened host specificity, pathogenicity, and immune evasion to vaccine-induced immunity. Here we compared humoral and cellular responses against SARS-CoV-2 VOC in subjects immunized with the DNA vaccine, INO-4800. INO-4800 vaccination induced neutralizing antibodies against all variants tested, with reduced levels detected against B.1.351. IFNγ T cell responses were fully maintained against all variants tested.